European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

HEIDELBERG,Germany,Dec. 25, 2024/PRNewswire/ -- European Wellness Biomedical Group (EWBG)has launched a new research initiative focused onKlotho, a protein with transformative potential inlongevity medicine. Led byProfessor Dr.Mike Chan, this project will explore Klotho's role in combating age-related diseases and its ability to regenerate critical organs, including thebrain,kidneys, andheart.

Klotho, identified in 1997, is emerging as a key protein in longevity and regenerative medicine. It plays a pivotal role in regulating oxidative stress, mineral metabolism, and inflammation. The research will investigate how boosting Klotho levels could help address chronic conditions likeneurodegenerative diseases,kidney failure, andheart disease, ultimately improving healthspan and extending lifespan.

"Klotho represents the next frontier inlongevity medicine,"saidProfessorMike Chan, Chief Scientist at EWBG."Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging."

Research Focus Areas

The new initiative will focus on three primary research areas:

• Neurological health: Investigating Klotho's neuroprotective effects and its potential to slow cognitive decline in diseases likeAlzheimer'sandParkinson's.
• Kidney function: Examining Klotho's role in regulating mineral metabolism and its regenerative potential in treatingchronic kidney disease (CKD).
• Cardiovascular health: Studying Klotho's influence on vascular function and its ability to preventvascular calcification, a key contributor toheart disease.

This research builds on existing collaborations atEWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.

Klotho: A Potential Breakthrough in Longevity Medicine

Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. UnlikeNAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.

As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.

ProfessorMike Chan: Leading the Charge in Klotho Research

ProfessorMike Chan, a leading expert instem cell therapyandlongevity medicine, is spearheading this groundbreaking initiative atEWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho's potential to revolutionize the treatment of age-related diseases. ThroughFCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combinestem cell technologyandKlotho proteinsto stimulate tissue regeneration in thebrain,kidneys, andheart.

"By harnessing Klotho's regenerative properties, we hope to address chronic conditions that were previously untreatable,"saidProfessor Chan."Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases."

The Future of Klotho in Longevity Medicine

The future ofKlotho-based therapieslooks promising, withProfessorMike ChanandEWBGat the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancinglongevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, fromneurodegenerative disease treatmenttokidney regenerationandcardiovascular health.

With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone oflongevity medicine, transforming how we approach aging and disease.ProfessorMike Chan'sleadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/european-wellness-biomedical-group-announces-new-klotho-research-initiative-led-by-prof-mike-chan-302338977.html

SOURCE European Wellness Biomedical Group